AbbVie, SpringWorks Join Forces To Conduct Multiple Myeloma Combo Therapy Trial

SpringWorks Therapeutics Inc SWTX entered into a clinical trial collaboration agreement with AbbVie Inc ABBV to evaluate SpringWorks' nirogacestat combination with ABBV-383 in relapsed or refractory multiple myeloma.

  • Gamma secretase inhibition helps prevent the cleavage and shedding of BCMA from the surface of myeloma cells. 
  • Under the terms of the agreement, AbbVie will sponsor and conduct the Phase 1b study to evaluate the combination's safety, tolerability, and preliminary efficacy.
  • AbbVie will also assume all costs associated with the study, other than expenses related to the manufacturing of nirogacestat and certain expenses related to intellectual property rights. 
  • AbbVie and SpringWorks will commence the Phase 1 trial in 1H 2022.
  • Price Action: SWTX shares closed at $71.66 on Thursday, while ABBV shares are up 0.25% at $124.46 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareContractsGeneralBriefsmultiple myelomaPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!